Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Non-Current Deferred Tax Liability (2023 - 2025)

Envoy Medical's Non-Current Deferred Tax Liability history spans 3 years, with the latest figure at -$276000.0 for Q4 2025.

  • Quarterly results put Non-Current Deferred Tax Liability at -$276000.0 for Q4 2025, down 15.48% from a year ago — trailing twelve months through Dec 2025 was -$276000.0 (down 15.48% YoY), and the annual figure for FY2025 was -$276000.0, down 15.48%.
  • Non-Current Deferred Tax Liability for Q4 2025 was -$276000.0 at Envoy Medical, down from -$239000.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of -$20000.0 in Q4 2023 to a low of -$276000.0 in Q4 2025.
  • The 3-year median for Non-Current Deferred Tax Liability is -$239000.0 (2024), against an average of -$178333.3.
  • The sharpest move saw Non-Current Deferred Tax Liability plummeted 1095.0% in 2024, then dropped 15.48% in 2025.
  • Year by year, Non-Current Deferred Tax Liability stood at -$20000.0 in 2023, then plummeted by 1095.0% to -$239000.0 in 2024, then decreased by 15.48% to -$276000.0 in 2025.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at -$276000.0, -$239000.0, and -$20000.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.